Literature DB >> 6491918

Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels.

F Bressolle, J Bres, M D Blanchin, R Gomeni.   

Abstract

Pharmacokinetics of the disinhibitory psychotropic agent sulpiride was investigated in 9 healthy male subjects after intramuscular administrations of 50, 100, and 200 mg in a 3 X 3 Latin square design. Plasma and urine concentrations were measured by HPLC for 36 and 48 h, respectively. The lowest detectable concentration was 10 ng/mL. Plasma concentration versus time and urinary excretion rate versus time curves were consistent with an open two-compartment body model, where mean +/- SD apparent half-lives of the absorption from muscle, lambda 1 distribution, and lambda 2 elimination phases were 6.96 +/- 2.64 min, 0.220 +/- 0.120 h, and 6.74 +/- 2.67 h, respectively. The initial volume of distribution was 0.145 +/- 0.063 L/kg, the steady-state volume of distribution was 0.639 +/- 0.184 L/kg, and the total clearance was 89.8 +/- 22.3 mL/min. The microscopic rate constants were k12 = 2.53 +/- 1.13 h-1, k21 = 0.674 +/- 0.197 h-1, and k10 = 0.635 +/- 0.298 h-1. Comparison of total clearance (89.8 mL/min), renal clearance (83.0 mL/min), and renal clearance of unbound drug (97.6 mL/min, f = 0.15) indicated that sulpiride is mainly excreted unchanged by the renal route, 93.1 +/- 6.6% of the administered dose being recovered unchanged in urine. Statistical evaluation of all the above parameters, determined at the three dosage levels, did not show any variations related to dose; the pharmacokinetics of sulpiride, over the dose range tested, was therefore linear and independent of dose. The two-compartment body model proposed was validated by digital computer simulation on a small digital computer (32K).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491918     DOI: 10.1002/jps.2600730826

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Response of i(kr) and HERG currents to the antipsychotics tiapride and sulpiride.

Authors:  Su-Hyun Jo; So-Young Lee
Journal:  Korean J Physiol Pharmacol       Date:  2010-10-31       Impact factor: 2.016

Review 2.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

3.  Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.

Authors:  F Bressolle; J Brès; G Mourad
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

4.  Development and Validation of a UPLC Method by the QbD-Approach for the Estimation of Rabeprazole and Levosulpiride from Capsules.

Authors:  Veera Raghava Raju Thummala; Raja Kumar Seshadri; Satya Sankarsana Jagan Mohan Tharlapu; Mrutyunjaya Rao Ivaturi; Someswara Rao Nittala
Journal:  Sci Pharm       Date:  2014-01-16

Review 5.  Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.

Authors:  Diogo Telles-Correia; António Barbosa; Helena Cortez-Pinto; Carlos Campos; Nuno B F Rocha; Sérgio Machado
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-02-06

6.  Pharmacokinetics of levosulpiride after single and multiple intramuscular administrations in healthy Chinese volunteers.

Authors:  Chuting Gong; Janvier Engelbert Agbokponto; Wen Yang; Ernest Simpemba; Xiaohong Zheng; Quanying Zhang; Li Ding
Journal:  Acta Pharm Sin B       Date:  2014-07-03       Impact factor: 11.413

7.  Binding of Sulpiride to Seric Albumins.

Authors:  Viviane Muniz da Silva Fragoso; Carla Patrícia de Morais Coura; Luanda Yanaan Hoppe; Marília Amável Gomes Soares; Dilson Silva; Celia Martins Cortez
Journal:  Int J Mol Sci       Date:  2016-01-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.